Cargando…

Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants

Mostrar otras versiones (1)

The rise of SARS-CoV-2 variants and the history of outbreaks caused by zoonotic coronaviruses point to the need for next-generation vaccines that confer protection against variant strains. Here, we combined analyses of diverse sequences and structures of coronavirus spikes with data from deep mutati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Eric, Chakraborty, Arup K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536555/ https://www.ncbi.nlm.nih.gov/pubmed/36156540 http://dx.doi.org/10.1371/journal.pcbi.1010563

Ejemplares similares

Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
por: Wang, Eric, et al.
Publicado: (2023)

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant
por: Lee, Cheryl Yi‐Pin, et al.
Publicado: (2021)

Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2
por: Li, Lili, et al.
Publicado: (2022)

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
por: Logue, James, et al.
Publicado: (2023)

Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2
por: Gao, Ang, et al.
Publicado: (2020)

Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variants
por: Liu, Jinbiao, et al.
Publicado: (2021)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
por: Ju, Bin, et al.
Publicado: (2023)

Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
por: Dalvie, Neil C., et al.
Publicado: (2021)

Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
por: Kapingidza, A. Brenda, et al.
Publicado: (2023)

Multivalent designed proteins protect against SARS-CoV-2 variants of concern
por: Hunt, Andrew C., et al.
Publicado: (2021)

A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants
por: Jiang, Linglei, et al.
Publicado: (2022)

A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
por: Jiang, Linglei, et al.
Publicado: (2022)

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens
por: Jiang, Hu-Dachuan, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Prediction of suitable T and B cell epitopes for eliciting immunogenic response against SARS-CoV-2 and its mutant
por: Agarwal, Vidhu, et al.
Publicado: (2021)

Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
por: Salehi, Mohammadreza, et al.
Publicado: (2022)

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
por: Joyce, M G, et al.
Publicado: (2021)

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
por: Liang, Qingtai, et al.
Publicado: (2022)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens
por: Yang, Leerang, et al.
Publicado: (2023)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV
por: Conti, Simone, et al.
Publicado: (2022)

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
por: Rice, Adrian, et al.
Publicado: (2022)

Erratum: A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
Publicado: (2022)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Tada, Takuya, et al.
Publicado: (2021)

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
por: Greaney, Allison J., et al.
Publicado: (2021)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
por: Greaney, Allison J., et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Structural prediction of chimeric immunogens to elicit targeted antibodies against betacoronaviruses
por: Simpson, Jamel, et al.
Publicado: (2023)

Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents
por: Sánchez-Sendra, Beatriz, et al.
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rchbjrbu9uuu8egmv5v626s2th